share_log

HC Wainwright & Co. Downgrades Lyell Immunopharma to Neutral, Lowers Price Target to $1

Benzinga ·  Jun 27 18:43

HC Wainwright & Co. analyst Mitchell Kapoor downgrades Lyell Immunopharma (NASDAQ:LYEL) from Buy to Neutral and lowers the price target from $6 to $1.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment